Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...

Under recommendations released Tuesday night, obesity would no longer be defined solely by BMI, a calculation of height and ...

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes ... Islanders in New Zealand to talk about ...

Beyond obesity, potential indications for these drugs include sleep apnea, addiction, Alzheimer’s disease, and metabolic dysfunction-associated steatohepatitis (MASH). New medications for these ...

Based in New York, Metsera (MTSR) is developing oral and injectable medications for the treatment of obesity and related conditions. Its lead drug candidate, MTE-097i, is an ultra-long-acting GLP ...

Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...

Eli Lilly and Novo Nordisk have been competing in the obesity ... for both drugs. Novo Nordisk’s Wegovy made a significant impact on the obesity market when it launched in 2021.